



PCT/GB2004/003183  
Pa/GB04/003183



INVESTOR IN PEOPLE

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 27 AUG 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the application is now proceeding in the name as identified herein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed *AmBrewster*

Dated 19 August 2004

WILLIAMSON COPY



INVESTOR IN PEOPLE

GB0317466.1

By virtue of a direction given under Section 30 of the Patents Act 1977, the application is proceeding in the name of

THE UNIVERSITY OF SHEFFIELD,  
Incorporated in the United Kingdom,  
Western Bank,  
SHEFFIELD,  
S10 2TN,  
United Kingdom

[ADP No. 00773812002]

Patents Form 1/77 CR

Patents Act 1977  
(Rule 16)

25 JUL 2003

RECEIVED BY FAX

The  
Patent  
Office25JUL03 E#25462-1 002973  
P01/7700 0.00-0317466-1**Request for grant of a patent***(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)*

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP9 1RH

## 1. Your reference

MON/P103083GB

## 2. Patent application number

*(The Patent Office will fill in this part)*

0317466

FILED: 22/7/04 25 JUL 2003

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*THE UNIVERSITY OF SHEFFIELD,  
Western Bank, SHEFFIELD, S10 2TNPatents ADP number *(if you know it)*THE UNIVERSITY OF NEWCASTLE,  
6 Kensington Terrace,  
NEWCASTLE-UPON-TYNE, NE1 7RU

If the applicant is a corporate body, give the country/state of its incorporation

## 4. Title of the invention

Use

5. Name of your agent *(if you have one)*

Harrison Goddard Foote

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*31 St Saviourgate  
YORK  
YO1 8NQPatents ADP number *(if you know it)*

07914237002 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country

Priority application number  
*(if you know it)*Date of filing  
*(day / month / year)*

## 7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
*(day / month / year)*8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 18 ✓

Claim(s) -

Abstract -

Drawing(s) 13 ✓

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

Harrison Goddard Ford

25 July 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Michelle O'Neill

01904 732120

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

USE

This invention relates to the use of an agent that inhibits the activity of an enzyme which mediates repair of single strand breaks in DNA in the treatment of certain  
5 forms of cancer in particular breast cancer.

Homologous recombination (HR) has been shown to play an important role in repair of damage occurring at DNA replication forks in mammalian cells (2). Thus, cells deficient in HR show retarded growth and exhibit higher level of genetic  
10 instability. It is believed that genetic instability due to loss of HR repair in human cancers significantly contributes to the development of cancer in these cells (1).

Post-transcriptional modification of nuclear proteins by poly(ADP-ribosyl)ation (PARP) in response to DNA strand breaks plays an important role in DNA repair,  
15 regulation of apoptosis, and maintenance of genomic stability.

Poly(ADP-ribose) Polymerase (PARP-1) is an abundant nuclear protein in mammalian cells that catalyses the formation of poly(ADP-ribose) (PAR) polymers using NAD<sup>+</sup> as substrate. Upon DNA damage, PARP-1 binds rapidly to a DNA  
20 single-strand break (SSB) and catalyses the addition of negatively charged PAR chains to itself (automodification) and other proteins (see (3, 4) for reviews). The binding of PARP-1 to SSBs is believed to protect DNA lesions from further processing until PARP-1 is dissociated from the break by the accumulated negative charge resulting from PAR polymers (5,6).

25

Although PARP-1 has been implicated in several nuclear processes, such as modulation of chromatin structure, DNA replication, DNA repair and transcription, PARP-1 knockout mice develop normally (7). Cells isolated from these mice exhibit a hyper recombination phenotype and genetic instability in the form of increased  
30 levels of SCE, micronuclei and tetraploidy (8-10). Genetic instability may also occur in these PARP-1 knockout mice through telomere shortening, increased frequency of chromosome fusion and aneuploidy (11), although all of these results could not be repeated in another set of PARP-1 knock-out mice (12). In the former mice knockout, PARP-1 null mutation rescue impaired V(D)J recombination in SCID mice (13).

These results support the view suggested by Lindahl and coworkers that PARP-1 has a protective role against recombination (5). They proposed that binding of PARP-1 to ssDNA breaks prevents the recombination machinery from recognizing and processing DNA lesions or, alternatively, that the negative charges accumulated following poly ADP-ribosylation repel adjacent recombinogenic DNA sequences. Only the latter model is consistent with inhibition of PARP-1 itself and expression of a dominant negative mutant PARP-1, inducing SCE, gene amplification and homologous recombination (HR [14-18]).

10 Studies based on treating cells with inhibitors of PARP-1 or cells derived from PARP-1 knockout mice indicate that the suppression of PARP-1 activity increases cell susceptibility to DNA damaging agents and inhibits strand break rejoining (3, 4, 8-11, 19, 20).

15 Inhibitors of PARP-1 activity have been used in combination with traditional anti-cancer agents such as radio therapy and chemotherapy (21). The inhibitors were used in combination with methylating agents, topoisomerase poisons and ionising radiations and were found to enhance the effectiveness of these forms of treatment. Such treatments, however, are known to cause damage and death to non cancerous or  
20 "healthy" cells and are associated with unpleasant side effects.

There is therefore a need for a treatment for cancer that is both effective and selective in the killing of cancer cells and which does not need to be administered in combination with radio or chemotherapy treatments.

25

The present inventors have surprisingly found that cells deficient in homologous recombination (HR) are hypersensitive to inhibitors of PARP-1 as compared to wild type cells. This is surprising since PARP-1 knockout mice live normally.

30 According to a first aspect of the invention there is provided the use of an agent which inhibits the activity of an enzyme which mediates repair of single strand breaks in DNA in the manufacture of a medicament for the treatment of diseases/conditions which are caused by a genetic defect in a gene which mediates homologous recombination.

In a further aspect the invention provides a method of treatment of a disease or condition in a mammal, including human, which is caused by a genetic defect in a gene which mediates homologous recombination, which method comprises  
5 administering to the mammal a therapeutically effective amount of an agent which inhibits the activity of an enzyme which mediates repair of single strand breaks in DNA.

10 In a preferred aspect said enzyme is PARP. In a further preferred aspect said agent is a PARP inhibitor or an RNAi molecule specific to PARP gene.

In a further preferred aspect, the use is in the treatment of cancer wherein the cancer is caused by a genetic defect in a gene which mediates homologous recombination.

15 Preferably the medicament is a pharmaceutical composition consisting of the PARP inhibitor in combination with a pharmaceutically acceptable carrier or diluent.

The specific sensitivity of HR tumours to PARP-1 inhibition means that normally dividing cells in the patient will be unaffected by the treatment. Treatment of HR  
20 defective cancer cells using a PARP inhibitor also has the advantage that it does not need to be administered as a combination therapy along with conventional radio or chemotherapy treatments thereby avoiding the side effects associated with these conventional forms of treatment.

25 A genetic defect in a gene which mediates homologous recombination may be due to a mutation in, the absence of, or defective expression of, a gene encoding a protein involved in HR.

30 In a further aspect, the invention further provides the use of a PARP inhibitor in the manufacture of a medicament for inducing apoptosis in HR defective cells.

In another aspect the invention provides a method of inducing apoptosis in HR defective cells in a mammal which method comprises administering to the mammal a therapeutically effective amount of a PARP inhibitor. By causing apoptosis in HR

defective cells it should be possible to reduce or halt the growth of a tumour in the mammal.

Preferably, the HR defective cells are cancer cells.

5

Cancer cells defective in HR may partially or totally deficient in HR. Preferably the cancer cells are totally deficient in HR.

10

The term "cancer" or "tumour" includes cancer of the lung, colon, pancreatic, gastric, ovarian, cervical, breast or prostate cancer. In a preferred aspect, the cancer is in a mammal, preferably human.

15

The cancer to be treated may be an inherited form of cancer wherein the patient to be treated has a familial predisposition to the cancer. Preferably, the cancer to be treated is gene-linked hereditary cancer. In a preferred embodiment of the invention the cancer is gene-linked hereditary breast cancer.

20

In a preferred aspect, the PARP inhibitor is useful in the treatment of cancer cells defective in the expression of a gene involved in HR. Genes with suggested function in HR include XRCC1, ADPRT (PARP-1), ADPRTL2 (PARP-2), CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 (see (2, 3, 5, 22-28) for reviews).

25

A gene involved in HR may be a tumour suppressor gene. The invention thus provides for the treatment of cancer cells defective in the expression of a tumour suppressor gene. Preferably, the tumour suppressor gene is BRCA1 or BRCA2.

30

Breast cancer is the most common cancer disease among women in the Western world today. Certain families have strong predisposition for breast cancer, which is often owing to an inherited mutation in one allele of either BRCA1 or BRCA2. However, these patients still maintain one functional allele. Thus, these patient develop normally



and have no phenotypic consequence from this mutation. However, in one cell, the functional allele might be lost, making this cell cancerous and at the same time deficient in homologous recombination (HR). This step is critical for the onset of a tumour [1].

5

The present inventors have surprisingly found that BRCA2 deficient cells are 100 times more sensitive to the PARP-1 inhibitor, NU1025, than wild type cells.

10 Thus in a preferred aspect, the invention provides the use of a PARP inhibitor in the manufacture of a medicament for the treatment of cancer cells defective in BRCA1 and/or BRCA2 expression.

The cancer cells to be treated may be partially or totally deficient in BRCA1 or BRCA2 expression. BRCA1 and BRCA2 mutations can be identified using multiplex PCR  
15 techniques, array techniques (29, 30) or using other screens known to the skilled person.

PARP inhibitors useful in the present invention may be selected from inhibitors of PARP-1, PARP-2, PARP-3, PARP-4, tankyrase 1 or tankyrase 2 (see 31 for a review).  
In a preferred embodiment, the PARP inhibitor useful in the present invention is an  
20 inhibitor of PARP-1 activity.

PARP inhibitors useful in the present invention include benzimidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinoline derivatives (e.g. 2-(4-hydroxyphenyl)benzimidazole-4-carboxamide (NU1085), 8-hydroxy-2-methylquinazolin-4-[3H]one (NU1025); 6(5H)phenanthridinone; 3 aminobenzamide; AG14361; benzimidazole-4-carboxamides (BZ1-6) and tricyclic lactam indoles (T11-5) [32]. Further inhibitors of PARP may be identified either by design [33] or the novel FlashPlate assay [34].  
25

30 The PARP inhibitor formulated as a pharmaceutical composition may be administered in any effective, convenient manner effective for targeting cancer cells including, for instance, administration by oral, intravenous, intramuscular, intradermal, intranasal, topical routes among others. Carriers or diluents useful in the pharmaceutical

composition may include, but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.

5 In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion. The inhibitor may be administered directly to a tumour or may be targeted to the tumour via systemic administration.

10 A therapeutically effective amount of the inhibitor is typically one which is sufficient to achieve the desired effect and may vary according to the nature and severity of the disease condition, and the potency of the inhibitor. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease.

15 For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01mg/kg to 10 mg/kg body weight, typically up to 0.1, 0.5, 1.0, 2.0 or 5.0 mg/kg body weight. Ultimately, however, the amount of inhibitor administered and the frequency of administration will be at the discretion of a physician.

20

A therapeutic advantage of using PARP inhibitors to treat cancer cells is that only very low doses are needed to have a therapeutic effect in treating cancer thereby reducing systemic build up of the inhibitors and any associated toxic effects.

25 A preferred aspect of the invention provides an agent which is an inhibitory RNA (RNAi) molecule.

30 A technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The RNAi molecule is typically derived from exonic or coding sequence of the gene which is to be ablated.

Preferably said RNAi molecule is derived from the nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

- a) a nucleic acid sequence as represented by the sequence in Figure 5, 6, 7, 8, 9 or 10, or fragment thereof;
- b) a nucleic acid sequence which hybridises to the nucleic acid sequences of Figure 5, 6, 7, 8, 9 or 10 and encodes a gene for PARP;
- c) a nucleic acid sequence which comprise sequences which are degenerate as a result of the genetic code to the nucleic acid sequences defined in (a) and (b).

Recent studies suggest that RNAi molecules ranging from 100-1000bp derived from coding sequence are effective inhibitors of gene expression. Surprisingly, only a few molecules of RNAi are required to block gene expression which implies the mechanism is catalytic. The site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.

The exact mechanism of RNAi action is unknown although there are theories to explain this phenomenon. For example, all organisms have evolved protective mechanisms to limit the effects of exogenous gene expression. For example, a virus often causes deleterious effects on the organism it infects. Viral gene expression and/or replication therefore needs to be repressed. In addition, the rapid development of genetic transformation and the provision of transgenic plants and animals has led to the realisation that transgenes are also recognised as foreign nucleic acid and subjected to phenomena variously called quelling (Singer and Selker, 1995), gene silencing (Matzke and Matzke, 1998), and co-suppression (Stam *et. al.*, 2000).

Initial studies using RNAi used the nematode *Caenorhabditis elegans*. RNAi injected into the worm resulted in the disappearance of polypeptides corresponding to the gene sequences comprising the RNAi molecule (Montgomery *et. al.*, 1998; Fire *et. al.*, 1998). More recently the phenomenon of RNAi inhibition has been shown in a number of eukaryotes including, by example and not by way of limitation, plants, trypanosomes (Shi *et. al.*, 2000) *Drosophila spp.* (Kennerdell and Carthew, 2000).

Recent experiments have shown that RNAi may also function in higher eukaryotes. For example, it has been shown that RNAi can ablate *c-mos* in a mouse oocyte and also E-cadherin in a mouse preimplantation embryo (Wianny and Zernicka-Goetz, 2000).

5

More preferably said RNAi molecule according has a length of between 10 nucleotide bases (nb) – 1000nb. Even more preferably said RNAi molecule has a length of 10nb; 20nb; 30nb; 40nb; 50nb; 60nb; 70nb; 80nb; 90nb; or 100bp. Even more preferably still said RNAi molecule is 21nb in length.

10

Even more preferably still the RNAi molecule comprises the nucleic acid sequence  
aaa agc cau ggu gga gua uga (PARP-1)

Even more preferably still the RNAi molecule consists of the nucleic acid sequence

15 aag acc aau cuc ucc agu uca ac (PARP-2)

Even more preferably still the RNAi molecule consists of the nucleic acid sequence  
aag acc aac auc gag aac aac (PARP-3)

20 The RNAi molecule may comprise modified nucleotide bases.

Preferred features of each aspect of the invention are as for each of the other aspects *mutatis mutandis*.

25 The present invention will now be described by way of example only with reference to the accompanying figures, wherein:

Figure 1 is a graph demonstrating that HR deficient cells are hypersensitive to the toxic effect caused by inhibition of PARP-1. Colony outgrowth of the Chinese hamster cell lines AA8 (wild-type), *irs1SF* (deficient in HR[4]), CXR3 (*irs1SF* complemented with XRCC3 [2]), V79 (wild-type), *irs1* (deficient in HR[5]) or *irs1X2.2* (*irs1* complemented with XRCC2 [1]) upon exposure to 3-AB (A), ISQ (B) or NU1025 (C). The means (symbols) and standard deviation (bars) of at least three experiments are shown. Colony outgrowth assay was used;

Figure 2 is a graph showing cell survival in the presence of PARP inhibitor NU1025 in wt V79 cells, BRCA2 deficient VC-8 cells and VC-8 cells complimented with functional BRCA2 gene (VC-8#13, VC-8+B2). Colony outgrowth assay was used;

5

Figure 3 is a graph showing cell survival in the presence of PARP inhibitor AG14361 in wt V79 cells, BRCA2 deficient VC-8 cells and VC-8 cells complimented with functional BRCA2 gene (VC-8#13, VC-8+B2);

- 10 Figure 4 is a histogram showing the percentage of the cells in apoptosis following a 72 hour incubation with NU1025;

Figure 5 is the human cDNA sequence of PARP-1;

- 15 Figure 6 is the human cDNA sequence of PARP-2;

Figure 7 is the human cDNA sequence of PARP-3;

Figure 8 is the human gDNA sequence of Tankyrase 1;

20

Figure 9 is the human mRNA sequence of Tankyrase 2;

Figure 10 is the human mRNA sequence of VPARP;

## EXAMPLES

### Homologous recombination deficient cells are hypersensitive to PARP-1 inhibition

To investigate the involvement of HR in cellular responses to inhibition of PARP-1, the effects of PARP-1 inhibitors on the survival of HR repair deficient cell lines were studied. It was found that cells deficient in HR (i.e., *irs1SF* which is defective in *XRCC3* or *irs1* which is defective in *XRCC2* [see Table 1] were very sensitive to the toxic effect of 3-aminobenzamide (3-AB) and to two more potent inhibitors of PARP-1: 1,5-dihydroxyisoquinoline (ISQ; [37]) or 8-hydroxy-2-methylquinazolinone (NU1025 [38, 39]) (Figure 1). The sensitivity in *irs1SF* cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional *XRCC3* gene (CXR3). Similarly, the sensitivity in *irs1* cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional *XRCC2* gene (*irs1X2.2*).

15

### BRCA2 deficient cells are hypersensitive to PARP-1 inhibition

The survival of BRCA2 deficient cells (VC8) and wild type cells (V79Z) in the presence of inhibitors of PARP-1 was investigated. It was found that VC8 cells are very sensitive to the toxic effect of NU1025 (Figure 2) or AG14361 (Figure 3). The sensitivity in VC8 cells was corrected by the introduction of a functional BRCA2 gene either on chromosome 13 (VC8#13) or on an overexpression vector (VC8+B2). This result demonstrates that the sensitivity to PARP-1 inhibitors is a direct consequence of loss of the BRCA2 function.

To investigate if inhibition of PARP-1 triggers apoptosis in BRCA2 deficient cells, the level of apoptosis 72 hours following exposure to NU1025 was investigated. It was found that NU1025 triggered apoptosis only in VC8 cells, showing that loss of PARP-1 activity in BRCA2 deficient cells triggers this means of death (Figure 4).

Table 1. Genotype and origin of cell lines used in this study.

Cell line	Genotype	Defect	Origin	Reference
AA8	wt	wt	CHO	[41]
irs1SF	<i>XRCC3</i> <sup>-</sup>	<i>XRCC3</i> <sup>-</sup> , deficient in HR	AA8	[41]
CXR3	<i>XRCC3</i> <sup>-</sup> + <i>hXRCC3</i>	wt	irs1SF	[41]
V79-4	wt	wt	V79	[40]
irs1	<i>XRCC2</i> <sup>-</sup>	<i>XRCC2</i> <sup>-</sup> , deficient in HR	V79-4	[40]
irs1X2.2	<i>XRCC2</i> <sup>-</sup> + <i>hXRCC2</i>	wt	irs1	[40]
V79-Z	wt	wt	V79	[42]
VC8	<i>BRCA2</i> <sup>-</sup>	<i>BRCA2</i> <sup>-</sup> , deficient in HR	V79-Z	[42]
VC8#13	<i>BRCA2</i> <sup>-</sup> + <i>hBRCA2</i>	wt	VC8	[42]
VC8+B2	<i>BRCA2</i> <sup>-</sup> + <i>hBRCA2</i>	wt	VC8	[42]

## Materials and Methods

### Cytotoxicity of BRCA2 cells to PARP inhibitors

#### 5 *Cell culture*

The *irs1*, *irs1X2.1* and V79-4 cell lines were a donation from John Thacker [40] and the AA8, *irs1SF* and CXR3 cell lines were provided by Larry Thompson [41].

- 10 The VC-8, VC-8+B2, VC-8#13 were a gift from Malgorzata Zdzienicka [42]. All cell lines in this study were grown in Dulbecco's modified Eagle's Medium (DMEM) with 10% Foetalbovine serum and penicillin (100 U/ml) and streptomycin sulphate (100 µg/mL) at 37°C under an atmosphere containing 5% CO<sub>2</sub>.

#### *Toxicity assay - colony outgrowth assay*

- 15 500 cells suspended in medium were plated onto a Petri dish 4 hours prior to the addition of 3-AB, ISQ or NU1025. ISQ and NU1025 were dissolved in DMSO to a final concentration of 0.2% in treatment medium. 7 - 12 days later, when colonies could be observed, these colonies were fixed and stained with methylene blue in methanol (4 g/l). Colonies consisting of more than 50 cells were subsequently  
20 counted.

#### *Toxicity assay - clonogenic survival assay*

Exponentially growing cells in 6-well plates were exposed to AG14361 in 1% DMSO or 1% DMSO alone in medium for 24 hours.

- 25 The cells were harvested by trypsinisation, counted and seeded at varying densities in 10 cm dishes in fresh medium in the absence of drug for colony formation. 7-10 days later the dishes were fixed with methanol:acetic acid 3:1 and stained with 0.4% crystal violet.  
Colonies were counted and the survival relative to 1%DMSO control treated cells  
30 calculated.



Apoptosis experiments

0.25x10<sup>6</sup> cells were plated onto Petri dishes and grown for 4 hours before treatment with NU1025. After 72 hours, cells were trypsinized and resuspended with medium containing any floating cells from that sample. The cells were pelleted by centrifugation and resuspended for apoptosis analysis with FITC-conjugated annexin-V and propidium iodine (PI) (ApoTarget, Biosource International) according to manufacturer's protocol. Samples were analysed by flow cytometry (Becton-Dickenson FACSsort, 488 nm laser), and percentage of apoptotic cells was determined by the fraction of live cells (PI-negative) bound with FITC-conjugated annexin-V.

10

## REFERENCES:

- [1] A.R. Venkiteswaran Cancer susceptibility and the functions of BRCA1 and  
5 BRCA2, *Cell* 108 (2002) 171-182.
- [2] C. Lundin, K. Brixon, C. Arnaudeau, N. Schultz, D. Jensen, M. Meuth and T. Helleday Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells, *Mol Cell Biol* 22 (2002) 5869-5878.
- 10 [3] D. D'Amours, S. Desnoyers, I. D'Silva and G.G. Poirier Poly(ADP-ribose)ylation reactions in the regulation of nuclear functions, *Biochem J* 342 (1999) 249-268.
- [4] Z. Herceg and Z.Q. Wang Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death, *Mutat Res* 477 (2001) 97-  
15 110.
- [5] T. Lindahl, M.S. Satoh, G.G. Poirier and A. Klungland Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks, *Trends Biochem Sci* 20 (1995) 405-411.
- [6] M.S. Satoh and T. Lindahl Role of poly(ADP-ribose) formation in DNA  
20 repair, *Nature* 356 (1992) 356-358.
- [7] S. Shall and G. de Murcia Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?, *Mutat Res* 460 (2000) 1-15.
- [8] Z.Q. Wang, L. Stingl, C. Morrison, M. Jantsch, M. Los, K. Schulze-Osthoff and E.F. Wagner PARP is important for genomic stability but dispensable in  
25 apoptosis, *Genes Dev* 11 (1997) 2347-2358.
- [9] C.M. Simbulan-Rosenthal, B.R. Haddad, D.S. Rosenthal, Z. Weaver, A. Coleman, R. Luo, H.M. Young, Z.Q. Wang, T. Ried and M.E. Smulson Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA,  
30 *Proc Natl Acad Sci U S A* 96 (1999) 13191-13196.
- [10] J.M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F.J. Oliver, M. Masson, A. Dierich, M. LeMeur, C. Walztinger, P. Chambon and G. de Murcia Requirement of poly(ADP-ribose) polymerase in recovery

from DNA damage in mice and in cells, *Proc Natl Acad Sci U S A* 94 (1997) 7303-7307.

- [11] F. d'Adda di Fagagna, M.P. Hande, W.M. Tong, P.M. Lansdorp, Z.Q. Wang and S.P. Jackson Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability, *Nat Genet* 23 (1999) 76-80.
- [12] E. Samper, F.A. Goytisolo, J. Menissier-de Murcia, E. Gonzalez-Suarez, J.C. Cigudosa, G. de Murcia and M.A. Blasco Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability, *J Cell Biol* 154 (2001) 49-60.
- [13] C. Morrison, G.C. Smith, L. Stingl, S.P. Jackson, E.F. Wagner and Z.Q. Wang Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis, *Nat Genet* 17 (1997) 479-482.
- [14] V. Schreiber, D. Hunting, C. Trucco, B. Gowans, D. Grunwald, G. De Murcia and J.M. De Murcia A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage, *Proc Natl Acad Sci U S A* 92 (1995) 4753-4757.
- [15] J.H. Kupper, M. Muller and A. Burkle Trans-dominant inhibition of poly(ADP-ribosyl)ation potentiates carcinogen induced gene amplification in SV40-transformed Chinese hamster cells, *Cancer Res* 56 (1996) 2715-2717.
- [16] J. Magnusson and C. Ramel Inhibitor of poly(ADP-ribose)transferase potentiates the recombinogenic but not the mutagenic action of alkylating agents in somatic cells in vivo in *Drosophila melanogaster*, *Mutagenesis* 5 (1990) 511-514.
- [17] A.S. Waldman and B.C. Waldman Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation), *Nucleic Acids Res* 19 (1991) 5943-5947.
- [18] A. Semionov, D. Cournoyer and T.Y. Chow Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts, *Nucleic Acids Res* 27 (1999) 4526-4531.
- [19] F. Dantzer, V. Schreiber, C. Niedergang, C. Trucco, E. Flatter, G. De La Rubia, J. Oliver, V. Rolli, J. Menissier-de Murcia and G. de Murcia Involvement of poly(ADP-ribose) polymerase in base excision repair, *Biochimie* 81 (1999) 69-75.

- [20] F. Dantzer, G. de La Rubia, J. Menissier-De Murcia, Z. Hostomsky, G. de Murcia and V. Schreiber Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1, *Biochemistry* 39 (2000) 7559-7569.
- [21] L. Tentori, I. Portarena and G. Graziani Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors, *Pharmacol Res* 45 (2002) 73-85.
- [22] T. Lindahl and R.D. Wood Quality control by DNA repair, *Science* 286 (1999) 1897-1905.
- [23] K.W. Caldecott DNA single-strand break repair and spinocerebellar ataxia, *Cell* 112 (2003) 7-10.
- [24] D. D'Amours and S.P. Jackson The Mre11 complex: at the crossroads of dna repair and checkpoint signalling, *Nat Rev Mol Cell Biol* 3 (2002) 317-327.
- [25] A.D. D'Andrea and M. Grompe The Fanconi anaemia/BRCA pathway, *Nat Rev Cancer* 3 (2003) 23-34.
- [26] S.P. Jackson Sensing and repairing DNA double-strand breaks, *Carcinogenesis* 23 (2002) 687-696.
- [27] R. Kanaar, J.H. Hoeijmakers and D.C. van Gent Molecular mechanisms of DNA double strand break repair, *Trends Cell Biol* 8 (1998) 483-489.
- [28] D.C. van Gent, J.H. Hoeijmakers and R. Kanaar Chromosomal stability and the DNA double-stranded break connection, *Nat Rev Genet* 2 (2001) 196-206.
- [29] S.L. Neuhausen and E.A. Ostrander Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2, *Genet Test* 1 (1997) 75-83.
- [30] G. Kuperstein, W.D. Foulkes, P. Ghadirian, J. Hakimi and S.A. Narod A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes, *Clin Genet* 57 (2000) 213-220.
- [31] A. Chiarugi Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited, *Trends Pharmacol Sci* 23 (2002) 122-129.
- [32] C.R. Calabrese, M.A. Batey, H.D. Thomas, B.W. Durkacz, L.Z. Wang, S. Kyle, D. Skalitzky, J. Li, C. Zhang, T. Boritzki, K. Maegley, A.H. Calvert, Z. Hostomsky, D.R. Newell and N.J. Curtin Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: Chemopotential and Pharmacological Studies, *Clin Cancer Res* 9 (2003) 2711-2718.
- [33] D. Ferraris, Y.S. Ko, T. Pahutski, R.P. Ficco, L. Serdyuk, C. Alemu, C. Bradford, T. Chiou, R. Hoover, S. Huang, S. Lautar, S. Liang, Q. Lin, M.X.


- Lu, M. Mooney, L. Morgan, Y. Qian, S. Tran, L.R. Williams, Q.Y. Wu, J. Zhang, Y. Zou and V. Kalish Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries, *J Med Chem* 46 (2003) 3138-3151.
- [34] K.J. Dillon, G.C. Smith and N.M. Martin A FlashPlate assay for the identification of PARP-1 inhibitors, *J Biomol Screen* 8 (2003) 347-352.
- [35] A.J. Pierce, R.D. Johnson, L.H. Thompson and M. Jasin XRCC3 promotes homology-directed repair of DNA damage in mammalian cells, *Genes Dev* 13 (1999) 2633-2638.
- [36] R.D. Johnson, N. Liu and M. Jasin Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination, *Nature* 401 (1999) 397-399.
- [37] G.M. Shah, D. Poirier, S. Desnoyers, S. Saint-Martin, J.C. Hoflack, P. Rong, M. ApSimon, J.B. Kirkland and G.G. Poirier Complete inhibition of poly(ADP-ribose) polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress, *Biochim Biophys Acta* 1312 (1996) 1-7.
- [38] R.J. Griffin, S. Srinivasan, K. Bowman, A.H. Calvert, N.J. Curtin, D.R. Newell, L.C. Pemberton and B.T. Golding Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), *J Med Chem* 41 (1998) 5247-5256.
- [39] S. Boulton, L.C. Pemberton, J.K. Porteous, N.J. Curtin, R.J. Griffin, B.T. Golding and B.W. Durkacz Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors, *Br J Cancer* 72 (1995) 849-856.
- [40] C.S. Griffin, P.J. Simpson, C.R. Wilson and J. Thacker Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation, *Nat Cell Biol* 2 (2000) 757-761.
- [41] R.S. Tebbs, Y. Zhao, J.D. Tucker, J.B. Scheerer, M.J. Siciliano, M. Hwang, N. Liu, R.J. Legerski and L.H. Thompson Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene, *Proc Natl Acad Sci U S A* 92 (1995) 6354-6358.

- [42] M. Kraakman-van der Zwet, W.J. Overkamp, R.E. van Lange, J. Essers, A. van Duijn-Goedhart, I. Wiggers, S. Swaminathan, P.P. van Buul, A. Errami, R.T. Tan, N.G. Jaspers, S.K. Sharan, R. Kanaar and M.Z. Zdzienicka Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions, Mol Cell Biol 22 (2002) 669-679.

5


1/13

Figure 1.



2/13


Figure 2.






3/13

Figure 3.



4/13

Figure 4



5

10

15

20

5/13

FIGURE 5

1 cgcgcgccca gccccggggg cagggaagc ctaaattacg gaattaccgc gagcaaggag  
 5 61 cgcggaatcg gggagcgtcc ggagctagot ggaatctcta ggcaggatgg tgaagggaat  
 121 ctttgcgaat tgtatctct gttgaaagt gaagtactta cctcagcagc agaagaaaaa  
 181 gctacaaact gacattaaag aaaaaggcgg aaagtcttcc ttctgttaa atctcagtg  
 241 cacaatata atcttagata atgtgatgt tctgagtcag tacaatga attctatcca  
 301 aaagaaccac gticatatg caaaccaga ttttatatgg aaatctatca gagaaaagag  
 361 actcttggat gtaagaait atgacttta taagccctg gacatcacac cacctcctga  
 10 421 tcagaaggcg agcagttotg aagtgaanao agaaggctta tgcccggaac gtccacaga  
 481 ggaggaagac actgtggaac tcaotgagtt tggatgcag aatgtgaaa ttctctatct  
 541 tctcaagat ttgaagttg caaaatataa caccttggag aaagtgggaa tggagggagg  
 601 ccaggaagct gtggtggtgg agcttoagt ttcgcgggac tccaggagct gtcttctct  
 661 gatactctca cacttctctc tggatgatgg catggagact agaagacagt ttgotataa  
 15 721 gaaaacctct gaagatgcaa gtgaatacti tgaataattac attgaagaao tgaagaaaca  
 781 aggatttcta ctaagagaac atttcacac tgaagcaacc caattagcat ctgaacaait  
 841 gcaagcattg othttggagg aagtcataaa tcaagcaact ctgagccaag aggtgagcga  
 901 ttatgtagag atgatttggg cagaggccot gggccacctg gaacacatgc ttctcaagcc  
 961 agtgaacagg attagcctca acgatgtgag caaggcagag gggattctcc ttctagtaaa  
 20 1021 ggcagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagttaa  
 1081 cagactgata cctcacaag gcaaatgcc caaagaagtg aacctgggac tattggctaa  
 1141 gaaagcagac ctctgcacg taataagaga catggtaait gtctgtgaaa ctaatttgc  
 1201 caaacccaac ccacatccc tggcaaaata ccgagotttg aggtgcaaaa ttgagcatgt  
 1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gttttgcaga atcatcaag  
 25 1321 taagagccca gtggatgtct tgcagatatt tagagttggc agagtgaatg aaaccacaga  
 1381 gttttgagc aaacttggta atgtgagcc ctgtttgat gttctctctg tacaaaacat  
 1441 cgtgggaatc ttgtgtcgag ggttcttcti aoccaaagta gtggaagato gtgtgtgca  
 1501 aagaacagac gloggaanacc ttggaagtgg gatitaitc agtgatcgo tcagtacaag  
 1561 tatcaagtao tcaaccccg gagagaaga tggcaccaga ctctctca ttgtgacgt  
 30 1621 agccctogga aagtgtatgg acttaocat gaaggactti tcttaactg aagcaccaco  
 1681 aggtacgac agtgtgcatg gatttcaca aaoagcctct gtcaccacag actttgagga  
 1741 tgaatgaatt gtgtctata aaaccaatca ggttaaaatg aaatatata ttaatttct  
 1801 catgcttga gatcagataa aggaatttca tctagtgtat cataotgaat tagaggaata  
 1861 cagacctgag tttaaaait ttcaaaagt tgaagaitac cagttaccag atgcaaaaac  
 35 1921 ttccagcagc accaaggccg gctccagga tgotctggg aacttggcto ctctggagga  
 1981 tctccacac aaaggagaga tcatagacac tctagcccag gtcattgtt ttacagata  
 2041 cacaataaa agtcacgtgc ccattgagc aaaaatatc ttctcttgg atgacaaggo  
 2101 cgtgtgtgt gcttogaag ccttcaicaa tgggaagcac atagtggag agattaaaga  
 2161 gaaggaagaa gcccagcaag agtacctaga agcctgacc caggccatg gogcttacct  
 40 2221 gatgagtcag gatgtccgg acgtttttac tgaagtgt ggaaactac cccctaaggo  
 2281 taaggttct ataaaaatta cctacatcac agaactcagc atcttgggca ctgttgggt  
 2341 cttttcatg cccgccacg tagcacctg gcaacaggac aaggotttga atgaaacct  
 2401 tcaggataca gttagaaga ttgtataaa agaaatagga acaaagcaaa gcttctctt  
 2461 gactatgtct attgagatgc cgtacgtgat tgaattcatt ttacagata ctcatgaact  
 45 2521 gaaacaaag cgcacagaot gcaagvtgt cartagcacc atggaaggca gctcottage  
 2581 cagcagtggg ttctctctc acatcggtt gtctgtgcc tatctccaa gaatgtgggt  
 2641 tgaaaaaac ccagaaaaag aaagcgagc ttgatgctt gttttcaac ccgatctga  
 2701 tctgaocct cctgacctag ccaatgagag cgaagtgaat attgtcttg actgtccag  
 2761 ttccatggag ggtgtgacat tottgcaagc caaggaaac gcttgoatg cgtgtctt  
 50 2821 ggtgggtgag aagcagaaag taaatattat ccagttoggc acaggttaca aggagctatt

6/13

2881 ttctatcct aagcatatca caagoaatca cggggcagca gagttoatca tctotgcac  
 2941 acctaccatg gggaacacag acttotggaa aacactccga tatcttagct tattgtacc  
 3001 tctcagaggg tcaagggaaca tctctctggt gtctgatggg cactctcagg atgagagcct  
 3061 gacattacag ctctgaaga ggagccgccc gcacaccagg ttattogcct gcggatagg  
 5 3121 ttctacagca aatogtcacg tcttaaggat ttgtcccag tgtggtgccc gactattga  
 3181 atattttaat gcaaatcca agcatagtig gaaaaatag atagaagacc aaatgaccg  
 3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc  
 3301 gcccagggcc ctgcaggccc cagcccagggt gccatccttg ttggcaatg atcgactcct  
 3361 tgtctatgga ttoattctc actgcaaca ggcaactctg tgtgcactaa ttoagagaa  
 10 3421 agaatttgt acaatggtgt cgactactga gottcagaag acaactggaa ctatgatcca  
 3481 caagctggca gcccagatgc taatcagaga ttatgaagat ggcattcttc aogaaatga  
 3541 aaccagtcct gagatgaaaa aacaaacott gaaatctctg attattaaac tcaagtaaga  
 3601 aaactctctc ataacacaat ttacaagctt tgtggcagtt gaaaaagggt atgagaatga  
 3661 gtcacotttt ctgatattc caaaagtgc tgaactatt gcaaaagaag atgtagactt  
 15 3721 cctgocctac atgagctggc aggggggaacc ocaagaagcc gtcagggaacc agtctcttt  
 3781 agcatcctct gagtggccag aattacgttt atccaaaga aaacatagga aaattccatt  
 3841 ttccaaaaga aaaatggaaat tatctcagcc agaatgttct gaagattitg aagaggatgc  
 3901 cttaggtgta ctaccagctt tcaatcaaaa ttggaaagt ggacgtgtgg aaaagctatt  
 3961 ggattiaagt tggacagagt catgtaaac aacagcaact gaaccactat ttaagaagt  
 20 4021 cagtccatgg gaaacatcta cttoiagctt ttictatt ttggtccgg cgttgcttc  
 4081 ctatctacc ccgactacc ggcctcacag tctgtcttc ttgctttg ootcatatg  
 4141 tcaggtagct agttcgggt cagctgtcc tccagacag ttgatgcct ctcaattoag  
 4201 coaaggccct gtgcttgga ctgtgtga ctggatcca cagtgccgt ctgtccacc  
 4261 aggacotccc cagaacccac ctctgcacc ctattgtgga attgtttt caggagotc  
 25 4321 attagctct gcacagtctg ctccactgca acatctgga ggttiacta ccaggccttc  
 4381 tctgtggcacc ttccctgagc tggattctcc ccagcttcat ttctctcttc ctacagacc  
 4441 tgatcccatc agaggtttg ggtttatca tccctctgt tactctctt ttatittca  
 4501 acctccgca gccctttga ctgccaacct taggctgcca atggcctctg ctitacatga  
 4561 ggctcttgc agtcagtccc ggaactaccc agtagatct tctctctag aagaatcgt  
 30 4621 aggcagtctc gaagggaagc gatgtcctgt ctgtctttt caaagttctg acacagaag  
 4681 tgatgagcta tcagaagtao ttcaagaag ctgctttta caataaaat gtgatacaa  
 4741 agatgacagt atccogtct tcttggaagt aaaagaagag gatgaatag tgtgcacaca  
 4801 aactggcag gatgtgtgc ctggacaga actctcagt ctacagacag aggatggctt  
 4861 ctggaaactt acaccagaac tgggaattat attaaatct aatacaatg gttgcacag  
 35 4921 cttctttaa caaaaggca ttcaatctct aggtgtaaa ggaagagaat gtctctgga  
 4981 cctaattgoc acaatgctgg tactaogtt tattogcacc aggttgaaa aagagggaat  
 5041 agtgtaaaa tcaatgatga aaatggatga ccttctatt tccaggaata ttccctggg  
 5101 tttagagca ataaagcaag caagtgaatg gtaagaaga actgaaggac agtaccatc  
 5161 tatctgccc cggottgaac tggggaaga ctgggaattt gccaccaagc agtggtggg  
 40 5221 actccagccc ataaagcactg tgcocctct tcatagatc ctccattaca gtoaggcta  
 5281 agtcaaatga aactgaattt taaattttt gcatgottct atgtagaaa taatcaatg  
 5341 ataagata ctataatga aacttattt aggttctt cagttagca attactgtt  
 5401 taaaaatta agtggagaa gaattactt aatcaacta caagcaataa taaatgaan  
 5461 cttaaat

7113

Figure 6

1 ctagaattca gcggccgctg aattctaggg ggccgggggg ccacggagca ccggccgggg  
 61 caggcgagga gcaataatg aaagcaaaag agttaataat ggcaaacgg ctcagagaaga  
 121 ctcttccoot gccaaagaaa ctctagatg ccagagacag gagicgaaa agatgcotgt  
 181 ggctggagga aaagotaata aggaacggac agaagacaag caagatggta tggcagggaag  
 241 gtcatgggco agcaaaaggg tctctgaatc tgtgaaggcc ttgctgttaa agggcaaaagc  
 301 tctctgggac ccagagtgtc cagccaagggt ggggaaggct catgtgtatt gtgaaggaaa  
 361 tgatgtctat gatgtcatgo taaatcagac caatctccag ttcaacaaca acaagtacta  
 421 tctgattcag ctattagang atgatgccca gaggaactto agtggttggg tgagatgggg  
 481 ccgagttggg aaatgggac agcaccggct ggtggcttgt tcaggcaato tcaacaaggc  
 541 caagggaato ttccagaaga aattccttga caaacgaaa aacaattggg aagatcgaga  
 601 aaagttigag aaggtgcotg gaaatatga tatgtacag atggactatg ccaccaatac  
 661 toaggatgaa gaggaaacaa aaaaagagga atctcttaa tctccotiga agccagagtc  
 721 acagctagat ctccgggtac aggagttaat aaagttgatc tgaatgttc aggcacatga  
 781 agaatgatg atggaaatga agtataatc caagaaagoo coactggga agctgacagt  
 841 ggcacaaatc aaggcagggt accagttctt taagaagatt gaggatigta ttccggctgg  
 901 ccagatgga agagcttca tggagcatg caatgaattc tacaccagga ttccgcatga  
 961 ctttgactc cgtactctc cactaatccg gacacagaag gaactgtcag aaaaaataca  
 1021 attactagag gcttggggag acattgaaat tctattaaag ctggtgaaa cagagctaca  
 1081 aagcccagaa caccattgg accaacacta tagaaacta catigtgct tgcgccccct  
 1141 tgaccatgaa agttacagt tcaaatgat ttccagtac ctacaatcta cccatgtcc  
 1201 cacacacago gactatacca tgacottgtt ggatttgtt gaagtggaga aggatggta  
 1261 gaaagaagcc ttoagagagg accttcataa caggatgctt ctatggcatg gttccaggat  
 1321 gagtaactgg gtgggaatct tgagccatgg gcttcgaat gccaccctg aagctccat  
 1381 cacaggttac atgttggga aaggaatcta ctttgcgac atgtctcca agagtgcac  
 1441 ttaactgtt gcctctcgc taaagaatac aggaactgtg ctctatcag aggtagctct  
 1501 aggtcaggtt aatgaactac tagaggcaa toctaaggcc gaaggattgc tcaaggtaa  
 1561 acatagcaco aaggggctgg gcaagatggc tccagttct gcccaottcg tcaacctgaa  
 1621 tgggagtaca gtgcatag gaccagcaag tgacacagga attctgaatc cagatggta  
 1681 taccctcaac tacaatgaat atattgtata taacccaac caggctccgta tgcggtagct  
 1741 ttraagggt cagtttaatt toctcagct gtggtgaatg ttgatctaa ataaaccaga  
 1801 gatctgatct tcaagcaaga aaataagcag tgtgtacti gtgaatttg tgatattia  
 1861 tgtaataaaa actgtacagg tctaaaaaa aaaaaaaa aaaaaaaa  
 //

Figure 7

1 tgggactggt cgctgactc ggctgccc agcctctgct tcacccact ggtggccaa  
 61 tagccgatgt ctaatcccc acacaagto atcccgccc tctgggattg ttgggaattc  
 121 totccotaat tcaogcctga ggtcatgga gatttgcag acctgggact gccctgggag  
 181 ggcacacaa ccaggccggg tggagccag gacototoco atgtccotgc ttcttggc  
 241 catggctoca aagccgaagc cctgggtaca gactgagggc cctgagaaga agaaggggc  
 301 gcaggcagga agggaggagg accccttcg ctccaccgt gaggcctca aggcatacc  
 361 cgcagagaag cgcataatcc ggttggatcc aacatgtca ctacagca acccgggac  
 421 ccaggtgtat gaggactaca actgacccct gaaccagacc aacatcgaga acaacaaoa  
 481 caagtictac atcatccagc tgcctcaaga cagcaaccgc ttctcaact gctgggaacg  
 541 ctggggccgt gtgggagagg tggccagtc aaagatoac cacttcaaa gctagaaga  
 601 tgcaagaag gacttgaga agaaatttc ggaagagacc aagaacaact gggcagagcg

8/13

661 ggaccacttt gtgtctcaoc cgggoaagta cacaottato gaagtacagg cagaggatga  
 721 ggcccaggaa gotgtgttga aggtggacag agggccagtg aggactgtga ctaagggggt  
 781 goagccctgc tccctggacc oagccaogca gaagctcatc actaacatct tcagcaagga  
 841 gatgtcaag aacaccatgg cctcatgga cctggatgig aagaagatgc coctgggaaa  
 901 gctgagcaag caacagattg cacgggggtt cgaggcoctg gaggcgotgg agggaggcoct  
 961 gaaaggccco acggatggtg gccaaaagcct ggaggagotg tctocacat titacaccgt  
 1021 catccggcac aactcggcc acagccagcc cccgoccatc aattccctg agcttctga  
 1081 ggccaagaag gacatgctgc tgggtgtggc ggaoatogag ctggcccagg ccctgcaggc  
 1141 agtctctgag caggagaaga oggtggagga ggtgocacac cccctggacc gagactacca  
 1201 gcttctoaag tgccagctgc agctgctaga ctctggagca octgagtaca aggtgataca  
 1261 gacctaacta gaacagactg gcagcaacca cagggtgccct acacttcaac acatctggaa  
 1321 agtaaaccaa gaaggggagg aagacagati ccaggccccc tccaaactgg gtaatoggaa  
 1381 gctgtgtggt catggcacca acatggccgt ggtggccgcc atcctcata gtgggctccg  
 1441 catcatgcca cattotggtg ggctgtgtgg oaagggoatc tactttgct cagagaacag  
 1501 caagtcagct ggatatgta ttggcatgaa gtgtggggcc caccatgtcg gctaatgtt  
 1561 cctgggtgag gtggccctgg gcagagagca ccatatcaac acggacaacc ccagcttgaa  
 1621 gagcccaact octggcttcg acagtgtcat tgcctggaggo caoaccgagc ctgatccgac  
 1681 coaggacact gagtggagc tggatggcca gcaagtgtg gtgcccagg gccagcctgt  
 1741 gccctgcca gagttcagaa gctccacat ctocagago gagtacctca totaccagga  
 1801 gagccagtgt cgcctgcct acctgctgga ggtccacctc tgaagtggcc cctgtcccc  
 1861 cggggctctg caaggctgga ctgtgatct caatcatct goocactct ggtacccta  
 1921 tatcactct ttttcaag aatacaatac gtgtgtta aotatagta ccatgtctga  
 1981 caagatcoct gaacttatgo ctocaaotg aaatttga tctttgaca catctgcca  
 2041 gtocctctcc tccagccca tggtaaccag cattgactc ttacttga taagggoagc  
 2101 tttataggt tccacatgta agtgagatca tgcagtgtt gtcttctgt gcoctggotta  
 2161 ttactctag cataatgtgc accgggttca cccatgttt cataaatgac aagatttct  
 2221 ccttaaaaa aaaaaaaa aaaaaaaa aaaaaaaa aaa

## 30 Figure 8

1 cgaagatggc ggcgtcgggt cgtctcago atcatcaacca ccatcatcaa caacagotcc  
 61 agcccgccc aggggcttca ggcgcgcgc cgcacactcc tcccccactc agccctggcc  
 121 tggcccccgg gacaaaccca gctctcaga cggccagcgg cctggccccc tccgctccc  
 181 ogcgacagg ootagcgtg ooggaggggg atggcagctg ggatccccc gacaggccc  
 241 gatccccgga cctggttgac ggtaccagct gttgcagtac caccagcaca atctgtaccg  
 301 tggccgcccg tccgtggtc ccagcgggtt ctacttcato tgcogctggg gtccgtccc  
 361 acccagccgg cagtggcagt aacattcac cgtcgtctc ttcttcccgt acttctct  
 421 catcttctc tccatcctcc cctggatcga gcttggcga gagcccccgg gggccggag  
 481 ttagcagcac agcaccactg gggcctgggg cagcaggaac tgggaagggt gtccagcag  
 541 tgagcggggc cctacgggaa ctgctggagg cctgtcggaa tggggacgtg tcccggtta  
 601 agaggctggg ggaacgggca aacgtaatg caaaggacat ggcggccggg aagtctctc  
 661 cctgcactt cgtgcaggt tttggaaagg aggatgtgtt agaacaotta ctacagatgg  
 721 gtgctaattg ccacgctgt gatgatggg gtctcatccc gcttcataat gctgttctt  
 781 ttggccatgc tgaagttgt agtctgttat tgtgccaagg agctgatcca aatggcaggg  
 841 ttaactggaa ctatacaccc ctgcatgaag ctgctattaa agggagagat gatgtgtgca  
 901 ttgtgtgct gcagcaggg gctgacccaa acattcggaa caotgatgg aaatcagcc  
 961 tggacccggc agatccctca gcaaaagctg tccctacagg tgaatacag aaagacgac  
 1021 tctagaagc tgcaggaagt ggtaatgaag aaaaaaat ggccttactg actcctcta  
 1081 atgtgaattg ccatgcaagt gatgggggaa agtcgautoc tttadactca gacgggggt  
 1141 acaacagagt tcgaatagtt cagcttcttc ttcagcatgg tctgatgtt catgcaaa  
 1201 acaagggtgg acttgtgct cttcataatg atgocatgga tctctggcag tttactcca  
 1261 aactgctact aaagcatgga gcttgtgtta atgtctgtc tttgttact agocatggg  
 1321 tgcacaggc tgcctccaaag aacgtgtag aagtctgtc tttgttact agocatggg  
 1381 ctgacccac gttagtcaac tgcacgggca aaagtgtgt ggatagggc ccaatccgg

913

1441 agdcttaggga gagattgaot tatgaattta aaggtatatto ttactacaa goagcagag  
 1501 aagcagactt agotaaagbt aaaaaaaoao tgcctctgga aatcattaat ttcaaaaoao  
 1561 cgcagtcctca tgaaaacagca ctgcactgtg ctgtggotcc tctgcatccc aaacgtaaa  
 1621 aagtgacaga attgttactt agaaaaggag caaatgttaa tgaaaaaoat aaagatttca  
 1681 tgaactccctt gcatgttgca ggcgaaggag cccataatga tgcctaggaa gtctgtcata  
 1741 agcatggcgd caagatgaat gcactggaca cctcggctca gactgctttg catagagcog  
 1801 ccttagcagg soacctgcag acotggcgcc tcttgctgag ttacggctct gacccotcca  
 1861 tcatctodct acaaaggctt acagcagcac agatgggcaa tgaagcagtg oagcagctc  
 1921 tgagtgtagg ttaoggtctt gaocctctca tcatctctt acaaaggctt acagcagca  
 1981 agatgggcaa tgaagcagtg cagcagattc tgagtggtta ttcttagata gtgatoatto  
 2041 tacttcagcc ttaahggctga tcttgagacg ggaagattta gaaggaaatc batocagcat  
 2101 gtctctactg tcaacatgaa gactacacct atactgtact ctgattgtga ttatgagct  
 2161 ttagaggcat cttaaagctg agatctggaa actgtgaagc aactttgtag ctctcaaat  
 2221 gtgaattgta gagacttaga gggcgggcat tccacgocct tacaotctgc agcaggctac  
 2281 aacagagtao adctatacgt acctctgatg ttgattatcg actcttagag gcatctaaag  
 2341 ctggagactt ggaagactgt agcaactt gtagctctca aatgttga tttagagact  
 2401 tagaggggcg gcatctacag ccttacaact tgcagcagg ctacaaocgo tggcttggtg  
 2461 tagagtacct gctacacac ggtgocgatg tccatgcaca agacaagggt ggttggtg  
 2521 ccttccataa tgcctgttca tatggacact atgagggtggc tgagotttca gtaaggcagt  
 2581 gggctctgtt caactgtggc gacttatgga aatttaoccc tctocacga gtagcagct  
 2641 aaggaaagta tgaactctg aagctctctt taaaaoatgg agdagatcca actaaaaaga  
 2701 adagagatgg aatatacact tgggatttgg taaaggaagg agacaaagat attcaggao  
 2761 taactgaagg ggaatgtctt ttgttggatg otgcaagaa gggctgtctg gcaagagt  
 2821 agaagctctg taccocagag aatatcaact gtagagacaa ctagggtag aattoaoc  
 2881 ctctgcacot ggcagcaggc tataataaoc tggaaagtag tgaatatct cttagagct  
 2941 gagctgatgt taatgccag gacaagggtg gtttaattcc tcttcatat ggggcatct  
 3001 atgggcatgt tgaatagcg gctttatgga taanaatacaa caogtgtgta aatgcaac  
 3061 taaagtggg gtttactcc otccatgag cagccagaa aggaaggagc agctgtgct  
 3121 ccttctctct agcgcctggt gtagaoccaa ccatgaaggc ccagggaagg cagacgct  
 3181 tggatctggc aacagctgac gatataagag ccttgctgat agatgocag cccccagag  
 3241 ccttacctac tggcttttaa octcaggcca ctgtagttag tgcctctctg atctocac  
 3301 catocacoc octctgcct tggctgtag caaocctcat cgggggtag cgcgcggga  
 3361 cagagttggc ogtaggagg gctccaatg caggggtag cgcgcggga acagaaagg  
 3421 aggaaggag agttgtggt cttgacatga atactagcca atttctaaa agccttggc  
 3481 ttgaacacct tggggtatct tttgaacag aacagattac actagatgtg ttgggtgata  
 3541 tgggtcatga agagttagaa gaaataggca tcaatgcata tgggacacg caaaattca  
 3601 tcaaggaggt agaaagact ttaggtggac aacagggaac caatcttat ttgactttt  
 3661 actgtgttaa tcaaggagc atttctgctg atcttgcctc agaaagataa gaatacagt  
 3721 cagtggaaga agagatgcaa agtactattc gagaacacag agatggtggt aatgctggc  
 3781 gcatcttcaa nagatcaaat gtcattcgaa tccaaaagt tgcacacag aagttaggg  
 3841 aggggtctg ccaacgacag aagggaagt ctgaggaaga tcaaaacat ttgacttagc  
 3901 gcatgtgtt tcatgggtct cottttattt atgocattat tcaaaaggg ttgtatgag  
 3961 gacatgcata cataggagga atgtttgggg ggggattta ttttgcgaa aactcctca  
 4021 aaagcaaoa atatgtttat ggaattggag gagggaacag ctgcctaca caaaggaca  
 4081 ggtcatgcta tatagttca agacaaatg tctctgttag agtgacocct gggaacat  
 4141 tctctgagtt tagcacatg aaaaatggcc acgocotoc agggnaocac tcagtcattg  
 4201 gtagaccgag cgtcaatggg ctggcatatg ctgaatatgt catctagaga ggaagacag  
 4261 cataccaga gtatcttato acttaocaga tcatgaagoo agaaagccot tccagacog  
 4321 caaagcogc agagcagaag acctagttaa tgcctgtctg tgaaggocag atcagattt  
 4381 aacotgggac tggattacag aggattgttt ctaataacaa catcaatatt ctagaagt  
 4441 ctgacagoc agaaataagc tgtctgtctt ctataaagca ttgotatagt g

Figure 9

1 cgcgcgcgt cgtagccga aacotgcca gccggtgccc ggccactgag cagcgcggg  
 61 acgacgtcac gtgcctcgc ggggtggac gtagctggca ggaggggcct tgcagctt  
 121 cgcgcgcgc tctttcagg acccggacgg cggattgctg ctgcctcgc cgcgcggg  
 181 cagcgcggg gtagggagcc cagcggaggg cgcgcgtggg cgcggocatg gtagtgc  
 241 gtagcgggt acagcaggga gccaaagcgc cggggcctg agcgcgtct ctccggggg  
 301 cctcgcctc ctgcctcgc ggcggggct ctgcctcgc ttgtgctgct tgttctggc  
 361 tgtggcgcg gccaggtat tgcgggtg cgcctgcgc ggcggggag cgccttgcg  
 421 gagcgcgcg gcagagcgc tggagcggc cgcgcagag ctgttagag cgtgcccga  
 481 cggggagctg gaacagatc agagcgtgt gacgcctgag aaggtgaaca gccgcgacac

10/13

541 ggogggcagg aatccaccc cgtgcoactt cggcgagggt ttggggcgga aagaogtagt  
 601 tgaatatttg cttcagaatg gtgcaaatgt ocaagoacgt gatgatgggg gocttattcc  
 661 tcttcataat gcatgctott ttgtoatgo tgaagtagtc aatctcotti tggacatgg  
 721 tgcagaccoc aatgctogag ataattggaa ttatactct ctocatgaag ctgcaattaa  
 5 781 aggaagatt gatgtttgca ttgtgctgtt aagcatgga gctgagcoca coactcgaaa  
 841 tacagatgga aggaagcat tggatttagc agatcoactt gccaaagcag tgottatgg  
 901 tgaatataag aaagatgaac tcttagaaag tggcaggagt ggcaatgaag aaaaantgat  
 961 ggctotactc acaccatlaa atgtcaactg ccacgcaagt gatggcagaa agtcaactcc  
 1021 attaoatttg gcagcaggat ataacagagt aaagattgta cagctgttac tgcacaatgg  
 10 1081 agotgatgtc catgctaaag ataaaggtga ttgtgtacca ttaocaaatg cctgttctta  
 1141 tggctattat gaagtaactg aacttttggc caagcatggt gcotgtgtaa atgcaatgga  
 1201 cttgiggcaa ttcactcttc ttcatgaggc agottotaag aacagggttg aagtatgtto  
 1261 tcttctctta agttatggtg cagacccaac actgctcaat tgtcacaata aaagtectat  
 1321 agacttggct cccacaccac agttaaaga aagattagca tatgaattta aaggccactc  
 15 1381 gttgctgcaa gctgcacgag aagotgatgt taotcgaatc aaaaaacatc tctctotgga  
 1441 aatggtgaat ttcaagcaco ctcaaacaca tgaacagca ttgcaattggt ctgctgcato  
 1501 tccatatocc aaaagaaagc aatatgtga actgttgcta agaaaaggag caaacatcaa  
 1561 tgaagagact aaagaattot tgactctctt gcacgtggca ttgagaaag ctcaataatga  
 1621 tttgttgtaa gtatgggtga aacatgaagc aaaggttaai gctotggata atcttggtca  
 20 1681 gacttctcta cacagagctg cataattgtg tcatctacaa acctggccgc tactcttgag  
 1741 ctatgggtgt gatcctaaca ttatatccot ttagggcttt actgctttac agatgggaaa  
 1801 tgaatatgta cagcaactcc tocaagagggt tatctcatta ggttaattcag aggcagacag  
 1861 acaattgctg gaagotgcaa aggtgggaga tctcgaact gtaaaaaaac tgtgtactgt  
 1921 tcagagtgtt aatgcagag acattgaagg gcgtcagctt acaccacttc atttgtagc  
 25 1981 tgggtataac agagtgtccg tgggtgaaat totgtacag catggagctg atgtgcacg  
 2041 taagataaa ggaggccttg taactttgca caatgcatgt tctatggac attatgaagt  
 2101 tgcagaactt ctgttaaaac atggagcagt agttaatgta gctgatttat ggaaatttac  
 2161 accttacct gaagcagocg caaaaggaaa atatgaattt tgcacacttc tgcocagca  
 2221 tgggtcagac cctacaaaaa aaaacaggga tggaaatact cctttggatc ttgttaaga  
 30 2281 tggagataca gatattcaag atctgcttag gggagatgca gctttgctag atgtgccaa  
 2341 gaaggggtgt ttgcccagag tgaagaagtt gtctctctct gataatgtaa atggccgga  
 2401 taoccaaaggc agacattcaa caoctttaca tttagcagct ggttataata atttagaagt  
 2461 tgcagagtat ttgttacaac acggagctga tgtgaatgcc caagacaaaag gaggacttat  
 2521 tctttacat aatgcagcat ottacgggca ttagatgta gcagctctac taataangta  
 35 2581 taatgcatgt gtcaatgcca cggacaaatg ggctttcaca octttgcacg aagcagccca  
 2641 aaagggagca acacagcttt gtgctttgtt gctagcccat ggagotgacc gactcttaa  
 2701 aaatcaggaa ggacaaacac ctttagattt agtttcagca gatgatgtca ggcctcttct  
 2761 gacagcagcc atgccccat ctgctctgcc ctctgttac aagcctoaag tgcctaatgg  
 2821 tgtgagaago ccaggagcca ctgcagatgc tctctcttca ggtccatota gcccatcaag  
 40 2881 ccttctgca gacagcagto ttgacaactt atctgggagt tticagaac tgtcttcagt  
 2941 agttagtca agtggacag aggtgtctto cagtttgag aaaaaggagg ttccaggagt  
 3001 agatttagc ataactcaat togtaaaggaa tcttggaact gagcacctaa tggatatatt  
 3061 tgagagagaa cagatcactt tggatgtatt agttgagatg gggcacaagg agctgaagga  
 3121 gatggaaac aatgcttatg gacataggca caaanotaatt aaaggagtcg agagacttat  
 45 3181 ctccggaoca caaggtctta acccatattt aacttigaa accctgtgta gtggaacaa  
 3241 tcttatagat ctgtctctg atgataaaga gtctcagctt gtggagggaag agatgcaag  
 3301 tacagtoga gagcaacag atggagggtca tgcagggtgga atcttcaaca gatacaatat  
 3361 tctcaagatt cagaaggttt gtaacaagaa aotatgggaa agatacactc accggagaaa  
 3421 agaagttct gaagaaaacc acaaccatgc caatgaacga atgctatttc atgggtctcc  
 50 3481 ttttgaat gcaattatcc acaaggctt ttagaaagg catgcgtaca taggtggtat



1113

3541 gtttggagct ggcatttatt ttgctgaaaa ctcttccaaa agcaatcaat atgtatatgg  
 3601 aattggagga ggtatgggt gtccagtica caaagacaga tottgttaca ttigccacag  
 3661 goagotgctc ttttccggg taaccttggg aaagtcitto ctgcagtica gtgcaatgaa  
 3721 aatggacat tctctccag gtcatoact agtactggt agggccagtg taaatggcct  
 5 3781 agcattagot gaatatgtta ttacagagg agaacaggct tatctgagt attaatatc  
 3841 ttaccagatt atgaggcctg aaggtatggt ogatggataa atagtattt taagaaacta  
 3901 attccactga aactaaaac atcaaacagc cagtggcctc taogtttiac tctttgctg  
 3961 aaaaaaaac atottgccc caggcctgtg gcaaaaggat aaaaatgtga acgaagtta  
 4021 acattctgac ttgataaagc ttaataatg tacagtgtt totaaatatt tctgtttt  
 10 4081 tcagcactt aacagatgcc atccagggt aaactgggtt gtctgtacta aattataaac  
 4141 agagttaot tgaaccttt atagtatg cattgattt aacaaactgt aatgccctca  
 4201 acagaactaa tttactaat acaatactgt gttctttaa acacagcatt tacaotgat  
 4261 acaattcat ttgtanaact gtaataaga gctttgtac tagocagta tttattaca  
 4321 ttgcttcta atataatct gtttagaac tgcagcgtt tacaanaatt tttcatatg  
 15 4381 attgtcatc tatactcat ctacatgt catgattgag tgatcttiac attgattcc  
 4441 agaggctaig ttcatgtt agttgggaaa gattgagta tcagattaa ttgccgatg  
 4501 ggagccttia tctgtcatta gaaatcttc tcatiaaga actatgaat atgotgaaga  
 4561 ttaattigt gataccttg tatgtatgag acacattca aagagctota actatgatag  
 4621 gtctgatta ctaaagaagc ttcttactg gcoicaatt ctagcttica ttttgaana  
 20 4681 tttctgcag tcttctgtg aaaaatagag caaagtctc ctgttitta gagaaactaa  
 4741 atctgtctg tgaacaatta ttgtgtctt tcatggaac ataagtagga ttttaacatt  
 4801 tccagggttg gaagggtat octaaatcat ttccaatct attctaatta cttaaatct  
 4861 aaaggggaaa aaaaaaatca caaacaggac tgggtagt tttatctaa gtatattt  
 4921 tctgttctt ttacttgg ttattgtg tatttatagc caatctatc atcatggta  
 25 4981 aactaacc agaatataa atgtagtgt ttacgtcc octoaggcct cotgaatggg  
 5041 caagtgcagt gaaacagggt cttctgtc ctgggtttc totcatgat gttatgcca  
 5101 attggaata tctgtcagt ttgtcaaca tatggtgacc acgctgtgc tcagtgtggc  
 5161 agotatagaa ggaatgtctg tccataaaa tgcatecct attctaata taacactct  
 5221 tteagggaag catgttaag catctgtta cagagacata catocattat ggcttggcaa  
 30 5281 tctctttat ttgtgactc tagctccct caaaglogag gaaagatct tactactta  
 5341 atgaggacat tcccatcac tgtctgtac agttacatt tatttaact tttatcagt  
 5401 ctgtanaata actggccctt tgcagtaac ttacataaa gtgctagaaa atcatgttc  
 5461 ttgtctgag taagagttaa tcagagtaag tgcattctg gattgtttc tgtatgtaa  
 5521 attatgata ttattaga agtcaaatcc tgatcttga gtgctttta tacagctctc  
 35 5581 taataattac aaatatcca aagtcattc ttgaacaca agtggagtat gccaatatt  
 5641 atatgaatt ttacagatt ctatgcttc aggtttata attagaagat aatgagagaa  
 5701 ttaatgggt ttatattac attatctct aactatgtg occatattac taccctatg  
 5761 agtgaatctg gaattgtt tcatgtgaaa tcatgtgt ctatagttt acaatactgc  
 5821 aaactgtgt attttatca aaccattgt taatgagtgt gttttccat gaatgaatat  
 40 5881 accgtggtt atagttagc atggcagcat tticagatag cttttgtt gtgggaagt  
 5941 tgggttttg gggggaggg gagtattagt acgtgtcag gaatagccta ctitataat  
 6001 atgggaatgc tttcttct gtttgggt tttttttt gaagtgaat ttaactttt  
 6061 gtgccagtag tactattata ccatcttca gtgtcttact tgaatgtat caaattccat  
 6121 accctcatt aattttaat aaaactgtc acttgtaaaa aaaaaaana aaaaaaana  
 45 6181 aaaaaaaa

Figure 10

1 ogcccgccca gcccggggg cagggaagc ctaaattaag gaattaccgc gagcaaggag

121B

61 cgcgggaatcg gggagcgtcc ggagctagct ggatcctota ggcaggatgg tgatgggaat  
 121 ctitgcaaat tgtatcttct gttgaaagt gaagtaacta cctcagcagc agaagaaaaa  
 181 gctacaaact gacattaagg aaatggcgg aaagtcttc ttctcgttaa atcctcagtg  
 241 cacacatata atcttagata atgotgatgt totgagtoag taccoactga attctatcca  
 5 301 aaagaaccac gttcatattg caaaccocaga tttatatgg aaatctatca gagaagaagag  
 361 actctggat gtaaagaatt atgacctta taagccctg gacatoacac cactcctga  
 421 tcagaaggcg agcagttctg aagtgaanao agaaggctta tgcocggaca gtgccacaga  
 481 ggaggaagac actgtgggac tcaotgagtt tggatgacag aatgttgaaa ttctcactt  
 541 tctcaagat ttgaagttg caaaatataa cacttggag aaagtgggaa tggagggagg  
 10 601 ccagggaagct gtgggtgggg agcttcagtg ttgcggggac tccagggaot gtctttcct  
 661 gatatoctca cacttctcc tggatgatgg catggagact agaagacagt ttgotataaa  
 721 gaaaacctct gaagatgcaa gtgaatacti tgaanaattac attgaagaac tgaagaaca  
 781 aggatticta ctaagagaac attacacac tgaagcaacc caattagcat ctgaacaatt  
 841 goaagcattg ctttggagg aagtcagtaa tcaagocact ctgagccaag aggtgagcga  
 15 901 tttagtagag atgatttggg cagagccctt gggccactg gaacacatgc ttctcaagcc  
 961 agtgaacagg attagctca acgatgtgag caaggcagag gggattctcc ttotagtaa  
 1021 ggcagcactg aanaatggag aaacagcaga goaattgcaa aagatgatga cagagtitta  
 1081 cagactgata cctcacaag gcacaatgcc caaagaagtg aacctgggac taitggctaa  
 1141 gaaagcagac ctctgccagc taataagaga catgggtaat gtctgtgaaa ctaatttgc  
 20 1201 caaaccacac ccacatccc tggccaaata ccgagcttt aggtgcaaaa ttgagcatgt  
 1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gttttgcaga atcatcacag  
 1321 taagagocca gtggatgtct tgcagatatt tagagtggc agagtgaatg aaaccacaga  
 1381 gttttgagc aaacttggta atgtgaggcc ctgttgcac ggttctctg tacaaaacat  
 1441 cgtgggaatc ttgtgtcag ggtgtcttt acccaagta gtggaagatc gtgggtgtgca  
 25 1501 aagaacagac gtccgaaacc ttggaagtgg gattatttc agtgattogc toagtacaag  
 1561 tatcaagatc tcaaccccg gagagacaga tggcaccaga ctctgtctca ttgtgacgt  
 1621 agccctcgga aagtgtatgg acttacatga gaaggacttt ccttaactg aagcacaac  
 1681 aggotacgac agtgtgcag gatttcaca aacagccct ctccaccag acttgagga  
 1741 tgatgaattt gttgtctata aaaccaatca ggttaaatg aaatatatta ttaatttc  
 30 1801 catgcctgga gataagataa aggaattica tctagtgtat catactgaat tagaggaata  
 1861 cagacctgag tttaaaatt ttcaaaagt tgaagattac cagtaccag atgocaaaac  
 1921 ttocagcagc acaaggccg gcctocagga tgcctctggg aacttgggtc ctctggagga  
 1981 tgtccacatc aaaggagaga tcatagacac ttagccag gtcattgttt ttacacata  
 2041 cacaataaa agtcacgtgc coattgaggo aaaaatatc ttctttgg atgacaaggc  
 35 2101 cgtgtgtgt gtcttcgaag ccttcatca tgggaagcac atagtggag agattaaaga  
 2161 gaaggaagaa gccagcaag agtacctaga agcgtgaac caggcccatg gcgcttacct  
 2221 gatgagtcag gatgtccgg aggttttao tgaagtgtt ggaactiac cccctaaggc  
 2281 taaggttct ataaaaatta cctacatcac agaactogo atctgggca ctgtgtgt  
 2341 ctlttcatg ccgcccacc tagcaccctg gcaacaggac aaggcttga atgaaaacct  
 40 2401 tcaggatata gtagagaaga ttgtataaa agaaatagga acaagcaaa gcttcttt  
 2461 gactatgtct attgagatgo cgtatgtgat tgaattcatt ttactgata cacatgaact  
 2521 gaaacaaaag cgcacagact gcaagctgt cattagcacc atggaaggca gctcctaga  
 2581 oagcagtggg ttctctcc acatgggtt gtctgtgccc tatctccaa gaatgtgggt  
 2641 tgaanaacat ccagaaaag aaagcggggc ttgatgctt gtcttcaac ccgatotoga  
 45 2701 ttogacotc cctgacctag ccagtggag cgaagtgtt atttgtttg actgtccag  
 2761 ttocatggag ggtgtgacat tcttgaagc caagcaaatc aacttgcag cgtgtctt  
 2821 ggtgggtgag aagcagaaag taaatattat ccagtggc acaggttaca aggagctatt  
 2881 ttogtatct aagcatatca caagcaatc oacggcagca gatttcaat tctgtcccac  
 2941 aactaccatg gggaacacag acttgggaa aacactocga tatottagct tattgtacc  
 50 3001 tgotcaggg tcaoggaaca tctctgtgt gtctgatgg cactccagg atgagagcct

1313

3061 gacattacag ctogtgaaga ggagccgccc gcacaccagg ttatgcct gcggtatcgg  
 3121 ttctacagca aatcgtcacg tcttaaggat ttgtoccag tgggtgccc gagtattga  
 3181 atattttaat gcaaaatcca agcatagtg gagaaacag atagaagacc aaatgaccg  
 3241 gctatgtct cggagtggc actctgtct cgtcaaatgg cagcaactca atccagatgc  
 5 3301 gcccgaggcc ctgcaggccc oagccaggt gccatccttg ttgcgaatg atcgactcct  
 3361 tgtctatgga ttcatctc actgcacaca agcaactctg tgtgcantaa tcaagagaa  
 3421 agaattttgt acaatgggtg cgaactactga gottcagaag acaactggaa ctatgatcca  
 3481 caagctggca gcccgagcic taatcagaga ttatgaagat ggcattcttc acgaaatga  
 3541 aaccagtcac gagatgaaaa acaaacctt gaactctctg attattaaac tcagttaaaga  
 10 3601 aaactctctc ataacacaat ttacaagctt tgggcaggt gagaaaagg atgagaatga  
 3661 gtcgccttt cctgatatic caaaagtct tgaacttatt gccaaagaag atgtagactt  
 3721 cctgccttac atgagctggc agggggagcc ccaagaagcc gtcagggaac agtctcttt  
 3781 agcatcctct gaggggccag aattacgtt atccaaacga aaactagga aaattccatt  
 3841 ttccaaaaga aaaatggaa tatctcagcc agaagtict gaagatttg aagaggatgg  
 15 3901 ctagggtga ctaccagct tcaatcaaa ttgggaagt ggaggtgtg aaaaagtatt  
 3961 ggatttaagt tggacagagt catgtaaac aacagcaact gaaccactat ttaagaaagt  
 4021 cagtcacagg gaaacatcta ctctagctt ttctctatt ttgctocgg ccgttggtc  
 4081 ctactitacc ccgactacco gcgctacag tctgtctcc ttgctttg cctcatatg  
 4141 tcaggtagct agttcgggt cagctgctcc tccagacag ttgatgcac ctcaattcag  
 20 4201 ccaaggccct gtgcctggca ctgtgtga ctgatccca cagtggcgt ctgtccac  
 4261 aggcctccc oagaaccac ctctgcac ctattgtgc attgtttt caggagctc  
 4321 attagctct gcacagtct ctccactga acatctgga ggcittacta ccaggcctc  
 4381 tgcggcacc ttccctgagc tggattctc ccagcttcat ttctctctc ctacagacc  
 4441 tgatcccat agaggtttg ggtctatca tccctctgt tactctctt ttcatthca  
 25 4501 acctccgca gcctcttga ctgccaact taggtgcca atggcctc ctctaccga  
 4561 ggtcttttg agtcagccc ggaactccc agtagatct tctctctag aagaatcag  
 4621 aggcagctc gaaggagtc gatgtctgt ctgtcttt oaaagtctg acacagaaag  
 4681 tgatgagcta tcagaagac ttcaagacag ctgctttta caataaagt gtgatacaa  
 4741 agatgacagt atccgtgt ctctggaatt aaaagaagag gatgaatag tctgcacaca  
 30 4801 aactggcag gatgtgtg ctggacaga actootcagt ctacagacag aggatggctt  
 4861 ctggaaact acacagaaac tgggactat attaatctt aatacaaatg gtttgcacag  
 4921 ctctttaa caaaaaggca ttcaactct aggtgtaaa ggaagagaat gtctctgga  
 4981 cctaattgcc acaatgtgg tactacagt tattgcacc aggttgaaa aagagggaat  
 5041 agtttcaa tcaatgatga aaatggatga cctctctt tccaggaata ttccctggc  
 35 5101 tttagaggca ataaagcaag oaagtgaat ggtaagaaga actgaaggac agtaccatc  
 5161 tatctgcca cggcttgaac tggggaacga ctgggactct gccaccaagc agttgtggg  
 5221 actccagccc ataagcaotg tgcocctct tcatagagtc ctocattaca gtcaaggcta  
 5281 agtcaaatga aactgaatt taaactttt gcagtctct atgtagaaa taatcaaatg  
 5341 ataatagata attataatga aacttactt aggttactt cagtgtagca attactgtc  
 40 5401 ttaaaaatta agtgaagaa gaattactt aatcaactaa caagcaataa taaaatgaa  
 5461 cttaaataa aaaaaaaaaa aaaaaaaaaa

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**